[INFANTILE CORTICAL HYPEROSTOSIS OR CAFFEY-DE TONI DISEASE. PRESENTATION OF 2 CASES SEEN IN COLOMBIA AND REVIEW OF THE LITERATURE].

G. Morillo,E. Sabogal,D. Melo

1964-04-01

Abstract:

What problem does this paper attempt to address?

Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies

Glen C Jickling,DaZhi Liu,Bradley P Ander,Boryana Stamova,Xinhua Zhan,Frank R Sharp

DOI: https://doi.org/10.1038/jcbfm.2015.45

2015-03-25

Abstract:Neutrophils have key roles in ischemic brain injury, thrombosis, and atherosclerosis. As such, neutrophils are of great interest as targets to treat and prevent ischemic stroke. After stroke, neutrophils respond rapidly promoting blood–brain barrier disruption, cerebral edema, and brain injury. A surge of neutrophil-derived reactive oxygen species, proteases, and cytokines are released as neutrophils interact with cerebral endothelium. Neutrophils also are linked to the major processes that cause ischemic stroke, thrombosis, and atherosclerosis. Thrombosis is promoted through interactions with platelets, clotting factors, and release of prothrombotic molecules. In atherosclerosis, neutrophils promote plaque formation and rupture by generating oxidized-low density lipoprotein, enhancing monocyte infiltration, and degrading the fibrous cap. In experimental studies targeting neutrophils can improve stroke. However, early human studies have been met with challenges, and suggest that selective targeting of neutrophils may be required. Several properties of neutrophil are beneficial and thus may important to preserve in patients with stroke including antimicrobial, antiinflammatory, and neuroprotective functions.

neurosciences,endocrinology & metabolism,hematology
[Evaluation of somatostatin or octreotide efficacy in the treatment of external pancreatic fistulas].

L. Brunaud,H. Sebbag,F. Marchal,A. Verdier,L. Bresler,J. Tortuyaux,P. Boissel

Annales de Chirurgie

Abstract:AIM OF THE STUDY To evaluate the prevalence of pancreatic pseudocyst after persistent fistula closure with somatostatin or octreotide. To compare the patient characteristics according to the subsequent presence or absence of pseudocyst. PATIENTS AND METHODS This retrospective study from January 1994 to August 1999 included 15 patients with an external pancreatic fistula. Fistula closure was observed for all patients with somatostatin or octreotide. CT scan was performed 66 +/- 34 days after the end of this treatment. RESULTS CT scan was normal in 9 patients (favorable group) and showed pancreatic pseudocyst (failure group) in 6 patients. Pancreatic fistula etiologies were different between the two groups. The 5 patients presenting pancreatic fistula after duodenopancreatectomy belonged to the favorable group. Six of the 10 patients presenting pancreatic fistula after pseudocyst drainage belonged to the failure group. There were no other differences between the two groups. CONCLUSION Persistent pancreatic fistula can be cured with somatostatin or octreotide. However, fistulas occurring after duodenopancreatectomy are more easily cured with somatostatin or octreotide than fistulas occurring after external pseudocyst drainage. Somatostatin or octreotide cannot be considered to be an effective treatment for pancreatic fistula occurring after pseudocyst drainage, despite the fact that 40% of them were permanently cured.
Targeting Rap1b signaling cascades with CDNF: Mitigating platelet activation, plasma oxylipins and reperfusion injury in stroke

Jui-Sheng Wu,Helike Lõhelaid,Chih-Chin Shih,Hock-Kean Liew,Vicki Wang,Wei-Fen Hu,Yuan-Hao Chen,Mart Saarma,Mikko Airavaara,Kuan-Yin Tseng

DOI: https://doi.org/10.1016/j.ymthe.2024.09.005

2024-11-06

Abstract:Cerebral reperfusion injury in stroke, stemming from interconnected thrombotic and inflammatory signatures, often involves platelet activation, aggregation and its interaction with various immune cells, contributing to microvascular dysfunction. However, the regulatory mechanisms behind this platelet activation and the resulting inflammation are not well understood, complicating the development of effective stroke therapies. Utilizing animal models and platelets from hemorrhagic stroke patients, our research demonstrates that human cerebral dopamine neurotrophic factor (CDNF) acts as an endogenous antagonist, mitigating platelet aggregation and associated neuroinflammation. CDNF moderates mitochondrial membrane potential, reactive oxygen species production, and intracellular calcium in activated platelets by interfering with GTP binding to Rap1b, thereby reducing Rap1b activation and downregulating the Rap1b-MAPK-PLA2 signaling pathway, which decreases release of the pro-inflammatory mediator thromboxane A2. In addition, CDNF reduces the inflammatory response in BV2 microglial cells co-cultured with activated platelets. Consistent with ex vivo findings, subcutaneous administration of CDNF in a rat model of ischemic stroke significantly reduces platelet activation, aggregation, lipid mediator production, infarct volume, and neurological deficits. In summary, our study highlights CDNF as a promising therapeutic target for mitigating platelet-induced inflammation and enhancing recovery in stroke. Harnessing the CDNF pathway may offer a novel therapeutic strategy for stroke intervention.
Abstract W MP90: Suppression of Endothelial Cell Alpha5Beta1 Integrin Prevents Ischemic Stroke Injury in Mice

Jill Roberts,Leon de Hoog,Gregory J Bix

DOI: https://doi.org/10.1161/str.46.suppl_1.wmp90

IF: 10.17

2015-02-01

Stroke

Abstract:Although breakdown of the blood-brain barrier (BBB) leads to significant injury after ischemic stroke, therapies that target this breakdown have been unsuccessful in improving patient outcomes. We hypothesize that the α5β1 integrin, a receptor that is conditionally upregulated in brain endothelial cells following ischemic stroke, could play a critical role in worsening ischemic injury and functional outcome by contributing to BBB breakdown. To investigate this hypothesis, we performed transient CCA/MCA occlusion in endothelial cell specific α5 integrin knockout (α5 KO) mice and wild-type (WT) mice treated with a α5β1 small peptide inhibitor ATN-161. Following experimental stroke, while WT control mice showed significant TTC-visualized infarcts by post-stroke day (PSD) 3, α5 KO mice and WT mice treated with ATN-161 had minimal to no discernible infarcts. Cresyl violet neuronal stain further demonstrated little to no tissue disruption and neuronal injury on PSD 1-3 in the α5 KO stroked brains. Furthermore, the BBB remained intact in the stroked α5 KO mice as evidenced by absent IgG staining in the brain parenchyma which was otherwise abundant in stroked WTs. Likewise, several markers of BBB stability such as the tight junction proteins Claudin-5 and ZO-1 were found to be upregulated in the α5 KO mice after stroke. Importantly, α5 KO mice did not have any difference in cerebrovascular anatomy or collateral brain blood flow that could otherwise account for these results. Finally, in vitro assays of brain endothelial cells exposed to oxygen-glucose deprivation (OGD) demonstrated that ATN-161 could prevent OGD-mediated increased endothelial cell permeability as measured by TEER and FITC-dextran, and enhanced beneficial Claudin-5 rearrangement at the cell surface. Taken together, these results suggest that suppression of α5 integrin in brain endothelial cells conveys significant resistance to experimental ischemic stroke injury due, at least in part, to enhanced BBB stability, and suggest that α5β1 integrin represents a novel and very promising therapeutic target for stroke.

peripheral vascular disease,clinical neurology
CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation

Junxiong Chen,Yingjun Ding,Chao Jiang,Rongmei Qu,Jonathan D. Wren,Constantin Georgescu,Xuejun Wang,Darlene N. Reuter,Beibei Liu,Cory B. Giles,Christoph H. Mayr,Herbert B. Schiller,Jingxing Dai,Christopher S. Stipp,Bharathiraja Subramaniyan,Jie Wang,Houjuan Zuo,Chao Huang,Kar-Ming Fung,Heather C. Rice,Arnoud Sonnenberg,David Wu,Matthew S. Walters,You-Yang Zhao,Tomoharu Kanie,Franklin A. Hays,James F. Papin,Dao Wen Wang,Xin A. Zhang

DOI: https://doi.org/10.1161/circresaha.123.323190

IF: 23.213

2024-04-03

Circulation Research

Abstract:Circulation Research, Ahead of Print. BACKGROUND:Tetraspanin CD151 is highly expressed in endothelia and reinforces cell adhesion, but its role in vascular inflammation remains largely unknown.METHODS:In vitro molecular and cellular biological analyses on genetically modified endothelial cells, in vivo vascular biological analyses on genetically engineered mouse models, and in silico systems biology and bioinformatics analyses on CD151-related events.RESULTS:Endothelial ablation ofCd151leads to pulmonary and cardiac inflammation, severe sepsis, and perilous COVID-19, and endothelial CD151 becomes downregulated in inflammation. Mechanistically, CD151 restrains endothelial release of proinflammatory molecules for less leukocyte infiltration. At the subcellular level, CD151 determines the integrity of multivesicular bodies/lysosomes and confines the production of exosomes that carry cytokines such as ANGPT2 (angiopoietin-2) and proteases such as cathepsin-D. At the molecular level, CD151 docks VCP (valosin-containing protein)/p97, which controls protein quality via mediating deubiquitination for proteolytic degradation, onto endolysosomes to facilitate VCP/p97 function. At the endolysosome membrane, CD151 links VCP/p97 to (1) IFITM3, which regulates multivesicular body functions, to restrain IFITM3-mediated exosomal sorting, and (2) V-ATPase, which dictates endolysosome pH, to support functional assembly of V-ATPase.CONCLUSIONS:Distinct from its canonical function in strengthening cell adhesion at cell surface, CD151 maintains endolysosome function by sustaining VCP/p97-mediated protein unfolding and turnover. By supporting protein quality control and protein degradation, CD151 prevents proteins from (1) buildup in endolysosomes and (2) discharge through exosomes, to limit vascular inflammation. Also, our study conceptualizes that balance between degradation and discharge of proteins in endothelial cells determines vascular information. Thus, the IFITM3/V-ATPase-tetraspanin-VCP/p97 complexes on endolysosome, as a protein quality control and inflammation-inhibitory machinery, could be beneficial for therapeutic intervention against vascular inflammation.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Integrin α5β1 inhibition by ATN-161 reduces neuroinflammation and is neuroprotective in ischemic stroke

Danielle N Edwards,Kathleen Salmeron,Douglas E Lukins,Amanda L Trout,Justin F Fraser,Gregory J Bix

DOI: https://doi.org/10.1177/0271678X19880161

2019-11-25

Abstract:Stroke remains a leading cause of death and disability with limited therapeutic options. Endothelial cell β 1 integrin receptors play a direct role in blood-brain barrier (BBB) dysfunction through regulation of tight junction proteins and infiltrating leukocytes, potentially mediated by β1 integrins. Following tandem transient common carotid artery/middle cerebral artery occlusion on wild-type mice, we administered the integrin a5b1 inhibitor, ATN-161, intraperitoneal (IP) injection at 1 mg/kg acutely after reperfusion, on post-stroke day (PSD)1 and PSD2. Systemic changes (heart rate, pulse distension, and body temperature) were determined. Additionally, infarct volume and edema were determined by 2,3-triphenyltetrazolium chloride and magnetic resonance imaging, while neurological changes were evaluated using an 11-point Neuroscore. Brain immunohistochemistry was performed for claudin-5, α5β1, IgG, and CD45 + cells, and quantitative polymerase chain reaction (qPCR) was performed for matrix metalloproteinase-9 (MMP-9), interleukin (IL)-1β, collagen IV, and CXCL12. ATN-161 significantly reduced integrin α5β1 expression in the surrounding peri-infarct region with no systemic changes. Infarct volume, edema, and functional deficit were significantly reduced in ATN-161-treated mice. Furthermore, ATN-161 treatment reduced IgG extravasation into the parenchyma through conserved claudin-5, collagen IV, CXCL12 while reducing MMP-9 transcription. Additionally, IL-1β and CD45 + cells were reduced in the ipsilateral cortex following ATN-161 administration. Collectively, ATN-161 may be a promising novel stroke therapy by reducing post-stroke inflammation and BBB permeability.

neurosciences,endocrinology & metabolism,hematology
Abstract WP168: Regulatory T Cell Transplantation Inhibits Cerebral Endothelial Inflammation in Mice Transient Focal Ischemia.

Peiying Li,Xiaoming Hu,Yu Gan,Feng Zhang,Yanqin Gao,Weimin Liang,Jun Chen

DOI: https://doi.org/10.1161/str.44.suppl_1.awp168

IF: 10.17

2013-01-01

Stroke

Abstract:INTRODUCTION: Cerebral endothelial cells express large amounts of adhesion molecules, attracting peripheral immune cells to infiltrate into brain parenchyma. Regulatory T cell (Treg) was recently reported as a key cerebroprotective immunomodulator in ischemic stroke. HYPOTHESIS: We assessed the hypothesis that Treg transplantation could protect the ischemic brain from endothelial inflammation via cell-cell interaction. METHODS: Transient focal cerebral ischemia was induced in C57/BL6 mice by unilateral middle cerebral artery occlusion (MCAO) for 60 minutes. Tregs (2x10 6 /mouse) or same numbers of splenocytes were injected intravenously at 2 hours after MCAO. RESULTS: We found that Treg transplantation could inhibit ICAM-1 expression on endothelial cells in vitro by 3.86±0.04 folds (P<0.01) and also at 24 hours after ischemia in vivo, resulting in ameliorated blood brain barrier damage and reduced infiltration of peripheral immune cells, such as T cells, macrophage, and neutrophils. Further study showed that depletion of CCR5 on Tregs reduced the protective effect of Treg transplantation. Real-time PCR demonstrated 134±46 folds (P<0.05) increase of CCL3, the ligand of CCR5 in the ischemic brain at 24 hours after stroke. Immunofluorescence showed that CCL3, possibly released from activated microglia, was closely associated with inflamed endothelial cells. In vitro migration test further revealed that widetype Tregs migrated across the endothelial cell layer towards CCL3; CCR5 -/- Tregs, however, failed to migrate. CONCLUSIONS: In conclusion, Treg transplantation protected the ischemic brain against ICAM-1 experssion on endothelial cells and profoundly inhibited peripheral immune cell infiltration. A novel contributing mechanism was defined that CCR5 and CCL3 mediated recruitment of Tregs to inflamed endothelial cells and played an important role in the cell-cell interaction between Tregs and endothelial cells.
Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia-induced brain injury

Yaqi Zhou,Xianqiu Zeng,Ge Li,Qiuhua Yang,Jiean Xu,Min Zhang,Xiaoxiao Mao,Yapeng Cao,Lina Wang,Yiming Xu,Yong Wang,Yu Zhang,Zhengshuang Xu,Chaodong Wu,Jiang-Fan Chen,Md Nasrul Hoda,Zhiping Liu,Mei Hong,Yuqing Huo

DOI: https://doi.org/10.1111/bph.14673

Abstract:Background and purpose: Inactivation of the gene for adenosine A2A receptors (ADORA2A for humans and Adora2a for rodents) protects against brain injury in experimental stroke. However, the cell-specific pathogenic effects of A2A receptors in thromboembolic stroke and the underlying mechanisms remain undefined. Here, we tested the hypothesis that inhibition of endothelial A2A receptors after thromboembolic stroke improves post-stroke outcomes via down-regulation of inflammation. Experimental approach: Thromboembolic stroke was induced by embolic middle cerebral artery occlusion in mice. Post-stroke outcomes were determined with neurological deficit scoring, infarct volume, inflammatory marker expression, brain leukocyte infiltration, blood-brain barrier (BBB) leakage, and oedema assessment. Anti-inflammatory effects of silencing the gene for A2A receptors or pharmacological antagonism of these receptors were assessed in vitro. Key results: Thromboembolic stroke induced Adora2a expression in the brain. Mice globally deficient in Adora2a (Adora2a-/- ) were resistant to stroke injury. Mice specifically deficient in endothelial Adora2a (Adora2aΔVEC ) showed reduced leukocyte infiltration, BBB leakage, and oedema after stroke, along with attenuated downstream proinflammatory markers, both in vivo and in vitro. The A2A receptor antagonist, KW 6002, also reduced brain injury and inflammation after stroke. Inactivation of ADORA2A inhibited endothelial inflammation via suppression of the NLRP3 inflammasome, down-regulating cleaved caspase 1 and IL-1β expression. Conclusions and implications: Specific inactivation of endothelial A2A receptors mitigated ischaemic brain injury and improved post-stroke outcomes, at least partly, through anti-inflammatory effects via blockade of NLRP3 inflammasome activity. Our findings may open new approaches to vascular protection after ischaemic stroke.
159 PD-1 Agonism as a Strategy to Prevent Neuroinflammation After Acute Large Vessel Occlusion

Jennifer E. Kim,Ryan P. Lee,Eli Yazigi,James Feghali,Lyla Atta,Ayush Pant,Idan Levitan,Risheng Xu,Kisha K. Patel,Nivedha Kannapadi,Pavan P. Shah,Eileen Kim,Justin M. Caplan,Gonzalez Fernando,Judy Huang,Michael Lim,Rafael Jesus Tamargo,Raymond Koehler,Lauren Janzie,Shenandoah Robinson,Christopher Mitchell Jackson

DOI: https://doi.org/10.1227/neu.0000000000002809_159

IF: 5.315

2024-04-01

Neurosurgery

Abstract:INTRODUCTION: Stroke is a leading cause of death and long-term disability worldwide. Acute ischemia results in a profound inflammatory response that is counterproductive to short- and long-term recovery. Programmed Death Protein 1 (PD-1) is an immune checkpoint that has been shown to be upregulated after acute cerebral injury, and—upon binding its ligand PD-L1—negatively regulates immune cells to limit the inflammatory response. METHODS: C57BL/6J mice underwent middle cerebral artery occlusion (MCAO) and were randomized into three arms: (1)sham surgery, (2)MCAO control, and (3)MCAO+PD-L1. Survival, brain water content, and volumetric MRI analysis of cerebral edema were measured. Brains were analyzed by flow cytometry to quantify PD-1 expression on infiltrating immune cells. Peripheral blood was harvested for single-cell RNA-sequencing. Blood from stroke patients was collected, and the frequency of PD-1+ monocytes was correlated to clinical outcomes. RESULTS: PD-L1 significantly decreased brain edema as measured by brain water content (p = 0.0277) and high-resolution MRI (p < 0.0001), and improved overall survival (p = 0.0022). PD-1+ monocytes are upregulated in the ischemic hemisphere, and appear to be critical mediators of edema. PD-L1 treatment decreased PD-1+ monocyte infiltration , while global PD-1 (PD-1-/-) and myeloid-specific knockout of PD-1 (PD-1f/fLysMcre) abrogated the treatment effect on edema. Single-cell RNA sequencing and differential expression analysis of peripheral monocytes revealed downregulation of multiple pro-inflammatory pathways in the treated mice versus the controls. Human correlative studies confirmed that PD-1+ monocytes were present in the peripheral blood of MCA stroke patients, and the frequency of this cell population correlated with post-stroke cerebral edema. CONCLUSIONS: Our results support PD-L1 as a novel therapeutic strategy for neuroinflammation and cerebral edema after acute ischemic stroke.

surgery,clinical neurology
Abstract WP295: Blocking the VCAM1-VLA4 Axis Prevents Cognitive Decline in a Mouse Model of Infarct-Induced Neurodegeneration

Kristy A Zera,Karen Bradshaw,Oliver Hahn,Aulden Foltz,Li Zhu,Todd Peterson,Hanadie Yousef,Davis Lee,Nima Aghaeepour,Tony Wyss-Coray,Marion S Buckwalter

DOI: https://doi.org/10.1161/str.55.suppl_1.wp295

IF: 10.17

2024-02-03

Stroke

Abstract:Stroke, Volume 55, Issue Suppl_1, Page AWP295-AWP295, February 1, 2024. Introduction:Infarct-induced neurodegeneration occurs chronically after stroke and can be prevented by inhibiting B cell influx. Vascular cell adhesion molecule 1 (VCAM1) facilitates immune cell diapedesis by binding very late antigen 4 (VLA4), and plasma levels are elevated after stroke in humans and mice. We hypothesized that chronic treatment with antibodies anti-VCAM1 or anti-VLA4 would reduce lymphocyte infiltration and prevent cognitive decline.Methods:Aged (10 month old) C57BL/6 male & female mice (N=9-10/group) underwent permanent middle cerebral artery occlusion and were dosed with anti-VCAM1, anti-VLA4, or control IgG every 3 days beginning 4 days after stroke for 10 weeks. Sham mice were also dosed with IgG. Barnes maze and Novel object were performed at -1, 1 and 6 weeks and single-cell RNA sequencing was performed on immune and endothelial cells at 10 weeks.Results:Blocking either VCAM1 or VLA4 reduced B cells 67% or 55%, respectively, compared to IgG treated stroked mice. Stroked mice treated with IgG developed a cognitive deficit in both Barnes maze and novel object by 6 weeks, while both anti-VCAM1 and anti-VLA4 treated mice performed comparably to sham animals in the Barnes maze (p=0.398; p=0.972, respectively). Similarly, sham IgG (p<0.0001), stroke anti-VCAM1 (p<0.0001) and VLA4 (p=0.0059) could all perform the novel object task. Single-cell sequencing of immune and brain endothelial cells demonstrated that most transcriptional changes occur in endothelial cells and not immune cells, and that anti-VCAM1 and anti-VLA4 induce similar transcriptional changes compared to control IgG after stroke. Specifically, both therapeutic antibodies restore heat shock protein expression (Dnaja1, Hsp90ab1, Hspa8) and decrease inflammatory genesCD74andIL1r1. Transcriptional changes also reflect increased translation andSox18upregulation, consistent with angiogenesis.Conclusion:Blocking either VCAM1 or VLA4 prevents infarct-induced neurodegeneration in aged mice. Changes in endothelial cell transcription and decreased immune cells in the brain may both contribute to therapeutic effects. Together, these findings establish the VCAM1-VLA4 axis as a promising target to prevent infarct-induced neurodegeneration.

peripheral vascular disease,clinical neurology
Inhibition of CCR1 attenuates neuroinflammation via the JAK2/STAT3 signaling pathway after subarachnoid hemorrhage

Qi Tian,Yina Li,Shi Feng,Chengli Liu,Yujia Guo,Guijun Wang,Heng Wei,Zhibiao Chen,Lijuan Gu,Mingchang Li

DOI: https://doi.org/10.1016/j.intimp.2023.111106

IF: 5.714

2023-11-05

International Immunopharmacology

Abstract:Background and purpose Neuroinflammation is an important mechanism underlying brain injury caused by subarachnoid hemorrhage (SAH). C-C chemokine receptor type 1 (CCR1)-mediated inflammation is involved in the pathology of many central nervous system diseases. Herein, we investigated whether inhibition of CCR1 alleviated neuroinflammation after experimental SAH and aimed to elucidate the mechanisms of its potential protective effects. Methods To analyze SAH transcriptome data R studio was used, and a mouse model of SAH was established using endovascular perforations. In this model, the selective CCR1 antagonist Met-RANTES (Met-R) and the CCR1 agonist recombinant CCL5 (rCCL5) were administered 1 h after SAH induction. To investigate the possible downstream mechanisms of CCR1, the JAK2 inhibitor AG490 and the JAK2 activator coumermycin A1 (C-A1) were administered 1 h after SAH induction. Furthermore, post-SAH evaluation, including SAH grading, neurological function tests, Western blot, the terminal deoxynucleotidyl transferase dUTP nick end labeling assay, and Fluoro-Jade B and fluorescent immunohistochemical staining were performed. Cerebrospinal fluid (CSF) samples were detected by ELISA. Results CCL5 and CCR1 expression levels increased significantly following SAH. Met-R significantly improved neurological deficits in mice, decreased apoptosis and degeneration of ipsilateral cerebral cortex neurons, reduced infiltrating neutrophils, and promoted microglial activation after SAH induction. Furthermore, Met-R inhibited the expression of p-JAK2, p-STAT3, interleukin-1β, and tumor necrosis factor-α. However, the protective effects of Met-R were abolished by C-A1 treatment. Furthermore, rCCL5 injection aggravated neurological dysfunction and increased the expression of p-JAK2, p-STAT3, interleukin-1β, and tumor necrosis factor-α in SAH mice, all of which were reversed by the administration of AG490. Finally, the levels of CCL5 and CCR1 were elevate in the CSF of SAH patient and high level of CCL5 and CCR1 levels were associated with poor outcome. Conclusion The present results suggested that inhibition of CCR1 attenuates neuroinflammation after SAH via the JAK2/STAT3 signaling pathway, which may provide a new target for the treatment of SAH.

pharmacology & pharmacy,immunology
CD200-CD200R1 inhibitory signaling prevents spontaneous bacterial infection and promotes resolution of neuroinflammation and recovery after stroke

Rodney M Ritzel,Abdullah Al Mamun,Joshua Crapser,Rajkumar Verma,Anita R Patel,Brittany E Knight,Nia Harris,Nickolas Mancini,Meaghan Roy-O'Reilly,Bhanu Priya Ganesh,Fudong Liu,Louise D McCullough

DOI: https://doi.org/10.1186/s12974-019-1426-3

2019-02-18

Abstract:Background: Ischemic stroke results in a robust inflammatory response within the central nervous system. As the immune-inhibitory CD200-CD200 receptor 1 (CD200R1) signaling axis is a known regulator of immune homeostasis, we hypothesized that it may play a role in post-stroke immune suppression after stroke. Methods: In this study, we investigated the role of CD200R1-mediated signaling in stroke using CD200 receptor 1-deficient mice. Mice were subjected to a 60-min middle cerebral artery occlusion and evaluated at days 3 and 7, representing the respective peak and early resolution stages of neuroinflammation in this model of ischemic stroke. Infarct size and behavioral deficits were assessed at both time points. Central and peripheral cellular immune responses were measured using flow cytometry. Bacterial colonization was determined in lung tissue homogenates both after acute stroke and in an LPS model of systemic inflammation. Results: In wild-type (WT) animals, CD200R1 was expressed on infiltrating monocytes and lymphocytes after stroke but was absent on microglia. Early after ischemia (72 h), CD200R1-knockout (KO) mice had significantly poorer survival rates and an enhanced susceptibility to spontaneous bacterial colonization of the respiratory tract compared to wild-type (WT) controls, despite no difference in infarct or neurological deficits. While the CNS inflammation was resolved by day 7 post-stroke in WT mice, brain-resident microglia and monocyte activation persisted in CD200R1-KO mice, accompanied by a delayed, augmented lymphocyte response. At this time point, CD200R1-KO mice displayed greater weight loss, more severe neurological deficits, and impaired motor function compared to WT. Systemically, CD200R1-KO mice exhibited signs of persistent infection including lymphopenia, T cell activation and memory conversion, and narrowing of the TCR repertoire. These findings were confirmed in a second model of acute neuroinflammation induced by systemic endotoxin challenge. Conclusion: This study defines an essential role of CD200-CD200R1 signaling in stroke. Loss of CD200R1 led to high mortality, increased rates of post-stroke infection, and enhanced entry of peripheral leukocytes into the brain after ischemia, with no increase in infarct size. This suggests that the loss of CD200 receptor leads to enhanced peripheral inflammation that is triggered by brain injury.
Development of endothelial-targeted CD39 as a therapy for ischemic stroke

Natasha Ting Lee,Ioanna Savvidou,Carly Selan,Ilaria Calvello,Amy Vuong,David K Wright,Robert Brkljaca,Abbey Willcox,Joanne S J Chia,Xiaowei Wang,Karlheinz Peter,Simon C Robson,Robert L Medcalf,Harshal H Nandurkar,Maithili Sashindranath

DOI: https://doi.org/10.1016/j.jtha.2024.04.023

Abstract:Background: Ischemic stroke is characterized by a necrotic lesion in the brain surrounded by an area of dying cells termed the penumbra. Salvaging the penumbra either with thrombolysis or mechanical retrieval is the cornerstone of stroke management. At-risk neuronal cells release extracellular adenosine triphosphate, triggering microglial activation and causing a thromboinflammatory response, culminating in endothelial activation and vascular disruption. This is further aggravated by ischemia-reperfusion injury that follows all reperfusion therapies. The ecto-enzyme CD39 regulates extracellular adenosine triphosphate by hydrolyzing it to adenosine, which has antithrombotic and anti-inflammatory properties and reverses ischemia-reperfusion injury. Objectives: The objective off the study was to determine the efficacy of our therapeutic, anti-VCAM-CD39 in ischaemic stroke. Methods: We developed anti-VCAM-CD39 that targets the antithrombotic and anti-inflammatory properties of recombinant CD39 to the activated endothelium of the penumbra by binding to vascular cell adhesion molecule (VCAM)-1. Mice were subjected to 30 minutes of middle cerebral artery occlusion and analyzed at 24 hours. Anti-VCAM-CD39 or control agents (saline, nontargeted CD39, or anti-VCAM-inactive CD39) were given at 3 hours after middle cerebral artery occlusion. Results: Anti-VCAM-CD39 treatment reduced neurologic deficit; magnetic resonance imaging confirmed significantly smaller infarcts together with an increase in cerebrovascular perfusion. Anti-VCAM-CD39 also restored blood-brain barrier integrity and reduced microglial activation. Coadministration of anti-VCAM-CD39 with thrombolytics (tissue plasminogen activator [tPA]) further reduced infarct volumes and attenuated blood-brain barrier permeability with no associated increase in intracranial hemorrhage. Conclusion: Anti-VCAM-CD39, uniquely targeted to endothelial cells, could be a new stroke therapy even when administered 3 hours postischemia and may further synergize with thrombolytic therapy to improve stroke outcomes.
Abstract WP306: Endothelial CD200 Signaling Protects Brain Against Ischemic Damage

Afzal Misrani,Conelius Ngwa,Abdullah Mamun,Rodney Ritzel,Louise McCullough,Fudong Liu

DOI: https://doi.org/10.1161/str.55.suppl_1.wp306

IF: 10.17

2024-02-03

Stroke

Abstract:Stroke, Volume 55, Issue Suppl_1, Page AWP306-AWP306, February 1, 2024. Background:Stroke is currently the leading cause of death and long-term disability in the US. Ischemic stroke induced inflammatory responses contribute to neuronal damage and stroke outcomes. CD200 and its receptor, CD200R, constitute an endogenous inhibitory signaling that is being increasingly recognized in studies of neuroinflammation in various central nervous system disorders. CD200 is a type 1 membrane glycoprotein that is broadly expressed by endothelia and neurons in the brain. We have previously reported the role of neuronal CD200 in stroke; in the present study, we examined the role of endothelial CD200 signaling in acute ischemic stroke.Hypothesis:Endothelial CD200 signaling is neuroprotective in acute ischemic stroke.Methods:Endothelial CD200 conditional knock out (CKO) mice were generated by breeding CD200 gene floxed mice with Cdh5Cremice. The mice were subjected to a 60-min transient middle cerebral artery occlusion (MCAO). Flow cytometry, Immunohistochemical staining, and western blotting were performed to assess the post-stroke inflammation; stroke outcomes (infarct volume and neurobehavioral deficits) were evaluated at 24 h or 72 h days after MCAO.Results:Flow cytometry results found CD200R was near null expressed on microglia at 24h and 72h after stoke and endothelial CKO of CD200 had no impact on peripheral immune cell development. Immunohistochemical staining confirmed CD200 was expressed on CD200 floxed but not on CD200 CKO endothelia. Western blot results showed CKO of CD200 from endothelia did not change BBB protein expression. CD200 CKO mice exhibited larger infarct size, worse neurological deficit scores (NDS), and more deficits in the tape adhesive/removal test than control mice 72h after MCAO (Fig. 1).Conclusions:Endothelial CD200 signaling protects brains against ischemic injury through a mechanism not directly related to microglial activation; instead, CD200R+circulating immune cells may be involved.

peripheral vascular disease,clinical neurology
Inactivation of endothelial adenosine A(2A) receptors protects mice from cerebral ischaemia-induced brain injury

Zhou Yaqi,Zeng Xianqiu,Li Ge,Yang Qiuhua,Xu Jiean,Zhang Min,Mao Xiaoxiao,Cao Yapeng,Wang Lina,Xu Yiming,Wang Yong,Zhang Yu,Xu Zhengshuang,Wu Chaodong,Chen Jiang-Fan,Hoda Md Nasrul,Liu Zhiping,Hong Mei,Huo Yuqing

DOI: https://doi.org/10.1111/bph.14673

IF: 7.3

2019-01-01

British Journal of Pharmacology

Abstract:Background and Purpose Inactivation of the gene for adenosine A(2A) receptors (ADORA2A for humans and Adora2a for rodents) protects against brain injury in experimental stroke. However, the cell-specific pathogenic effects of A(2A) receptors in thromboembolic stroke and the underlying mechanisms remain undefined. Here, we tested the hypothesis that inhibition of endothelial A(2A) receptors after thromboembolic stroke improves post-stroke outcomes via down-regulation of inflammation. Experimental Approach Thromboembolic stroke was induced by embolic middle cerebral artery occlusion in mice. Post-stroke outcomes were determined with neurological deficit scoring, infarct volume, inflammatory marker expression, brain leukocyte infiltration, blood-brain barrier (BBB) leakage, and oedema assessment. Anti-inflammatory effects of silencing the gene for A(2A) receptors or pharmacological antagonism of these receptors were assessed in vitro. Key Results Thromboembolic stroke induced Adora2a expression in the brain. Mice globally deficient in Adora2a (Adora2a(-/-)) were resistant to stroke injury. Mice specifically deficient in endothelial Adora2a (Adora2a(Delta VEC)) showed reduced leukocyte infiltration, BBB leakage, and oedema after stroke, along with attenuated downstream proinflammatory markers, both in vivo and in vitro. The A(2A) receptor antagonist, KW 6002, also reduced brain injury and inflammation after stroke. Inactivation of ADORA2A inhibited endothelial inflammation via suppression of the NLRP3 inflammasome, down-regulating cleaved caspase 1 and IL-1 beta expression. Conclusions and Implications Specific inactivation of endothelial A(2A) receptors mitigated ischaemic brain injury and improved post-stroke outcomes, at least partly, through anti-inflammatory effects via blockade of NLRP3 inflammasome activity. Our findings may open new approaches to vascular protection after ischaemic stroke.
Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-β1 expression

Li Pang,Wen Ye,Xiao-Ming Che,Blake J. Roessler,A. Lorris Betz,Guo-Yuan Yang

DOI: https://doi.org/10.1161/01.str.32.2.544

2001-01-01

Abstract:Background and Purpose—Chemokines have been shown to play an important role in leukocyte and monocyte/macro- phage infiltration into ischemic regions. The purpose of this study is to identify whether overexpression of the active human transforming growth factor-b1 (ahTGF-b1) can downregulate expression of monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1a (MIP-1a), and intercellular adhesion molecule-1 (ICAM-1) and reduce ischemic brain injury. Methods—Overexpression of transforming growth factor- b1 (TGF-b1) was achieved through adenoviral gene transfer. Five days after adenoviral transduction, the mouse underwent 30 minutes of middle cerebral artery occlusion followed by 1 to 7 days of reperfusion. TGF-b1, MCP-1, MIP-1a, and ICAM-1 were detected by enzyme-linked immunosorbent assay and immunohistochemistry. Infarct areas and volumes were measured by cresyl violet staining. Results—MCP-1 and MIP-1 a expression is increased after middle cerebral artery occlusion, and double-labeled immunostaining revealed that MCP-1 is colocalized with neurons and astrocytes. Viral-mediated TGF-b1 overexpres- sion was significantly greater at measured time points, with a peak at 7 to 9 days. The expression of MCP-1 and MIP-1a, but not ICAM-1, was reduced in the mice overexpressing ahTGF-b 1( P,0.05). Furthermore, infarct volume was significantly reduced in the mice overexpressing ahTGF-b 1( P,0.05). Conclusions—This study demonstrates that MCP-1 and MIP-1 a expressed in the ischemic region may play an important role in attracting inflammatory cells. The reduction of MCP-1 and MIP-1a, but not ICAM-1, in the mice overexpressing ahTGF-b1 suggests that the neuroprotective effect of TGF-b1 may result from the inhibition of chemokines during cerebral ischemia and reperfusion. (Stroke. 2001;32:544-552.)
TCRαβ + NK1.1 - CD4 - CD8 - double-negative T cells inhibit central and peripheral inflammation and ameliorate ischemic stroke in mice

Dan Tian,Yuhualei Pan,Yushang Zhao,Huan Wang,Yue Tian,Lu Yang,Wen Shi,Chengjie Zhang,Yanbing Zhu,Yongbo Zhang,Songlin Wang,Dong Zhang

DOI: https://doi.org/10.7150/thno.80307

IF: 11.6

2023-01-01

Theranostics

Abstract:Background: Excessive immune activation leads to secondary injury and impedes injured brain recovery after ischemic stroke. However, few effective methods are currently used for equilibrating immune balance. CD3+NK1.1-TCRβ+CD4-CD8- double-negative T (DNT) cells which do not express NK cell surface markers are unique regulatory cells that maintain homeostasis in several immune-related diseases. However, the therapeutic potential and regulatory mechanism of DNT cells in ischemic stroke are still unknown. Methods: Mouse ischemic stroke is induced by occlusion of the distal branches of the middle cerebral artery (dMCAO). DNT cells were adoptively transferred intravenously into ischemic stroke mice. Neural recovery was evaluated by TTC staining and behavioral analysis. Using immunofluorescence, flow cytometry, and RNA sequencing, the immune regulatory function of DNT cells was investigated at different time points post ischemic stroke. Results: Adoptive transfer of DNT cells significantly reduces infarct volume and improves sensorimotor function after ischemic stroke. DNT cells suppress peripheral Trem1+ myeloid cell differentiation during the acute phase. Furthermore, they infiltrate the ischemic tissue via CCR5 and equilibrate the local immune balance during the subacute phase. During the chronic phase, DNT cells enhance Treg cell recruitment through CCL5, eventually developing an immune homeostatic milieu for neuronal recovery. Conclusions: DNT cell treatment renders the comprehensive anti-inflammatory roles in specific phases of ischemic stroke. Our study suggests that the adoptive transfer of regulatory DNT cells may be a potential cell-based therapy for ischemic stroke.

medicine, research & experimental
Retraction Statement. Paper by Manizate et al., entitled ‘Liver functional reserve estimation: state of the art and relevance to local treatments‘ Oncology 2010;78(suppl 1):131-134, DOI: 10.1159/000315241

Cathy Mast,R. Ramanathan,D. Feinstein,P. Rosen,N. Maass,M. Weigel,A. Wenners,W. Jonat,C. Mundhenke,C. Schem,D. Bauerschlag,K. Tiemann,F. Schaefer,S. Hanson,M. Muth

DOI: https://doi.org/10.1159/000366537

2014-09-03

Oncology

Abstract:
Inhibition Of Integrin Vla-3 And Tetraspanin Cd151 Protects Against Neutrophil-Mediated Endothelial Damage

Chelsey Ciambella,Hadley Witt,Catherine M. Dickinson,Madison L. Smith,Nicholas Coburn,Nicholas Messina,Daithi S. Heffernan,Minsoo Kim,Jonathan S. Reichner

DOI: https://doi.org/10.1097/shk.0000000000002397

2024-07-19

Shock

Abstract:In a healthy host, a localized injury or infection generates an inflammatory response initiated by the site-specific recruitment of blood neutrophils ( 1 ). This begins a well-orchestrated series of cellular and humoral events that, over time, result in resolution and return to homeostasis. Under conditions of systemic or prolonged illness, including sepsis, this temporary regulated response becomes persistent and results in tissue accumulation of highly activated neutrophils that can cause collateral tissue damage with risk of organ failure ( 1–3 ). A significant component of tissue damage stems from the neutrophilic targeting of microvessels, which lose control of selective permeability that is essential to maintenance of organ function ( 4–7 ). Because of the importance of vascular function, together with the unmet need for therapeutic management of critical illness, finding new mechanisms that contribute to vascular damage by activated neutrophils is of basic and clinical relevance. Given the essential antimicrobial role neutrophils play during infection, the elimination of these cells or suppression of their function in order to protect from collateral damage is contraindicated in the septic patient. The challenge is to identify molecular targeting strategies that can attenuate the collateral damage caused by activated neutrophils yet preserve their benefit to immune defense.

surgery,peripheral vascular disease,hematology,critical care medicine
SODIUM AZIDE AFFECTS METHYLENE BLUE CONCENTRATION IN Salmonella typhimurium and Saccharomyces cerevisiae

W. Koch,G. Bass

DOI: https://doi.org/10.1111/j.1751-1097.1984.tb08869.x

1984-05-01

Photochemistry and Photobiology

Abstract:Abstract— Since 1974, the quenching effect of azide (N3‐) has been widely used to infer participation of excited singlet oxygen (1O2) as a major reactive species in microbial photodynamic action studies. We report herein that N3‐ causes a rapid, concentration‐dependent release of at least one heterocyclic aromatic photosensitizer, methylene blue, from Salmonella typhimurium. A similar phenomenon of lesser magnitude was also observed in Saccharomyces cerevisiae. This process may account in part for the azide photoprotective effects in vivo.

[INFANTILE CORTICAL HYPEROSTOSIS OR CAFFEY-DE TONI DISEASE. PRESENTATION OF 2 CASES SEEN IN COLOMBIA AND REVIEW OF THE LITERATURE].

Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies

[Evaluation of somatostatin or octreotide efficacy in the treatment of external pancreatic fistulas].

Targeting Rap1b signaling cascades with CDNF: Mitigating platelet activation, plasma oxylipins and reperfusion injury in stroke

Abstract W MP90: Suppression of Endothelial Cell Alpha5Beta1 Integrin Prevents Ischemic Stroke Injury in Mice

CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation

Integrin α5β1 inhibition by ATN-161 reduces neuroinflammation and is neuroprotective in ischemic stroke

Abstract WP168: Regulatory T Cell Transplantation Inhibits Cerebral Endothelial Inflammation in Mice Transient Focal Ischemia.

Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia-induced brain injury

159 PD-1 Agonism as a Strategy to Prevent Neuroinflammation After Acute Large Vessel Occlusion

Abstract WP295: Blocking the VCAM1-VLA4 Axis Prevents Cognitive Decline in a Mouse Model of Infarct-Induced Neurodegeneration

Inhibition of CCR1 attenuates neuroinflammation via the JAK2/STAT3 signaling pathway after subarachnoid hemorrhage

CD200-CD200R1 inhibitory signaling prevents spontaneous bacterial infection and promotes resolution of neuroinflammation and recovery after stroke

Development of endothelial-targeted CD39 as a therapy for ischemic stroke

Abstract WP306: Endothelial CD200 Signaling Protects Brain Against Ischemic Damage

Inactivation of endothelial adenosine A(2A) receptors protects mice from cerebral ischaemia-induced brain injury

Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-β1 expression

TCRαβ + NK1.1 - CD4 - CD8 - double-negative T cells inhibit central and peripheral inflammation and ameliorate ischemic stroke in mice

Retraction Statement. Paper by Manizate et al., entitled ‘Liver functional reserve estimation: state of the art and relevance to local treatments‘ Oncology 2010;78(suppl 1):131-134, DOI: 10.1159/000315241

Inhibition Of Integrin Vla-3 And Tetraspanin Cd151 Protects Against Neutrophil-Mediated Endothelial Damage

SODIUM AZIDE AFFECTS METHYLENE BLUE CONCENTRATION IN Salmonella typhimurium and Saccharomyces cerevisiae